GENEVA and SYDNEY, Australia, Sept. 5 /PRNewswire/ -- Proteome Systems and GeneBio (Geneva Bioinformatics) today announced the signing of an exclusive agreement for the worldwide distribution of Proteome Systems' GlycoSuite database. The GlycoSuiteDB(TM) is the world's first relational database of protein glycosylation; glycosylation being a diverse group of protein modifications important in protein function and diseases such as cancer.
``We are excited to appoint GeneBio as the exclusive distributor of the GlycoSuiteDB,'' said Keith Williams, CEO of Proteome Systems. ``GeneBio's range of products represent best practice in protein databases, and we are delighted to have GlycoSuiteDB as the product distributed by GeneBio which will benchmark protein glycosylation information.''
Keith Williams continued, ``Because of a lack of well structured information, glycosylation has been seen as an important scientific area but one in which the commercial relevance is unclear. A significant problem was that information concerning glycosylation was scattered throughout the literature in thousands of scientific publications. In GlycoSuiteDB, Proteome Systems has curated a large part of the scientific literature on protein glycosylation to make it available in an easily searchable form. For the first time, this allows researchers to ask large-scale questions such as ''Which proteins show glycosylation changes during cancer?`` This has the potential to accelerate the understanding of complex diseases and to illuminate commercially important issues.''
Erik J. Baas, CEO of GeneBio, said, ``Proteome Systems has quickly established itself as a leading company in Proteomics, and we are delighted to have exclusive distribution of this high-quality database. The GlycoSuiteDB is a natural extension of the SWISS-PROT protein database, and in combination these will provide researchers with unparalleled opportunities to address commercially important problems in the field of proteomics.''
Geneva Bioinformatics (GeneBio) S.A. is a rapidly growing bioinformatics company based in Geneva, Switzerland. Founded in November 1997, GeneBio's mission is to provide high quality proteomics databases, software tools, services and customized solutions through in-house development and strategic alliances with key research institutions and companies. GeneBio is the exclusive commercial representative for the Swiss Institute of Bioinformatics (SIB), and provides key proteomic tools and protein databases like SIB's SWISS-PROT, PROSITE and SWISS-2DPAGE, the protein analysis software package Melanie-3, and the world famous ExPASy proteomics web server that provides access to a suite of proteomics tools and databases. These high-value proteomics databases and services, along with innovative, state of the art products and services developed in-house, form the foundation of GeneBio's product line. For more information about GeneBio's products, view the World Wide Web at genebio.com .
Proteome Systems Limited is a biotechnology company with approximately 50 employees, headquartered in Sydney, Australia. It is one of a small group of companies globally with the capacity to conduct large scale proteomics projects. Proteome Systems is a leading innovator in the development of proteomics instrumentation and consumables and is also pioneering bioinformatic aspects of proteomics. By combining its innovative technology and informatics, Proteome Systems lays claim to having one of the world's best proteomics discovery platforms. It has strategic alliances with Dow AgroSciences (Indianapolis USA), MicroFab Technologies (Plano Texas USA) and Shimadzu Corporation (Japan). Proteome Systems is currently expanding its high throughput capacity to bring even greater speed to its discovery programs. |
